Washington Takes Aim at the Weight-Loss Ad
The FDA and HHS targeted deceptive drug ads in 2025, including GLP-1 telehealth marketing. What the crackdown covered and what patients should watch.
The boom that put GLP-1 drugs in every feed also filled those feeds with claims regulators call misleading. In 2025, the government pushed back.
The same surge that made GLP-1 drugs a cultural phenomenon also produced a flood of advertising — much of it, in regulators’ view, overstated. In September 2025, the FDA and the Department of Health and Human Services announced a broad campaign against deceptive direct-to-consumer drug marketing, and GLP-1 advertising sat near the center of it.
The scale of the action
The numbers were striking for an area that had drawn light enforcement for years. The agencies said they were issuing thousands of warning letters and roughly a hundred cease-and-desist letters targeting deceptive pharmaceutical ads. The move revived a scrutiny of direct-to-consumer promotion that had gone largely dormant.
The targets were not only traditional drugmakers. Several GLP-1 telehealth companies received letters. The FDA’s argument in those cases was pointed: misleading promotion could render a compounded product misbranded, and a misbranded drug is unlawful to sell. That framing tied the advertising crackdown directly to the parallel effort winding down compounded semaglutide and tirzepatide.
Why GLP-1 marketing drew fire
The shortage years bred a marketing style built for social media — glossy before-and-afters, guaranteed results, minimal risk information, and prescriptions issued after a brief online questionnaire. Much of it promoted compounded versions of the drugs at prices well below the branded products. Regulators objected to claims that overstated benefit, understated risk, or blurred the line between an FDA-approved medicine and a compounded copy.
State officials joined in. Attorneys general in California, Texas, New York, and elsewhere opened their own investigations into direct-to-consumer weight-loss platforms, examining advertising practices and prescribing standards.
The rules are being reasserted
Strip away the specifics, and the campaign is about restoring ordinary drug-marketing law to a market that grew up outside it. Pharmaceutical advertising in the U.S. is supposed to present a fair balance — accurate benefits paired with meaningful risk disclosure — and to distinguish approved products from those that are not. Fast-moving telehealth promotion during a shortage often did neither.
The enforcement does not ban GLP-1 advertising. It insists that such advertising follow the same rules that govern any prescription drug: no overstated benefit, honest risk information, no misrepresentation of what the patient is actually buying.
What it means for patients
Read alongside the compounding crackdown, the message is consistent. Regulators are trying to reimpose structure on a category that expanded faster than oversight could follow.
For the person scrolling past a too-good-to-be-true weight-loss ad, the practical guidance is unglamorous but sound. Prefer licensed pharmacies and legitimate prescribers. Expect real risk information, not just transformation photos. Be wary of guaranteed outcomes and of “generic” or “compounded” GLP-1 offers pitched at prices far below the branded drugs, particularly now that the legal basis for most compounding has ended. An ad that hides the risks is telling you something about the seller.
Frequently asked questions
Why is the FDA cracking down on GLP-1 ads? During the shortage years, GLP-1 marketing — especially from telehealth platforms selling compounded versions — often overstated benefits, understated risks, or blurred the line between approved drugs and compounded copies. In September 2025, the FDA and HHS moved to reassert ordinary drug-advertising law.
Are GLP-1 telehealth ads legal? Telehealth advertising is legal, but it must follow the same rules as any prescription-drug promotion: accurate benefits, fair risk disclosure, and no misrepresentation. The FDA sent letters to several GLP-1 telehealth marketers, arguing that misleading promotion could render a compounded product misbranded and unlawful to sell.
How can I spot a misleading weight-loss ad? Watch for guaranteed results, dramatic before-and-after images with little or no risk information, and “generic” or “compounded” GLP-1 offers priced far below the branded drugs. Legitimate drug advertising presents a fair balance — real benefits alongside real risks.
What should I look for in a legitimate GLP-1 provider? Prefer licensed pharmacies and prescribers who evaluate you properly, provide clear risk information, and dispense FDA-approved products. Be especially cautious now that the legal basis for most GLP-1 compounding has ended.
Sources
- U.S. Food and Drug Administration and U.S. Department of Health and Human Services — announcement on deceptive direct-to-consumer pharmaceutical advertising, September 9, 2025.
- Holland & Knight — legal analysis of the FDA/HHS DTC advertising enforcement action, 2025.
- U.S. Food and Drug Administration — warning and cease-and-desist letters to GLP-1 telehealth marketers, 2025.
- State attorney general offices (California, Texas, New York) — investigations into direct-to-consumer weight-loss platforms, 2025–2026.